Investor Relations
A generational opportunity in oncology pharmaceutical technology.
PTC Oncology is positioned to build one of the UK's most capable oncology drug development platforms — anchored by a lead Nivolumab biosimilar programme targeting a market projected to exceed USD 45 billion by 2033.
Investor Deck
Development & Production of Oncology Monoclonal Antibody Drugs
Full pitch deck covering scope, innovation, financial summary, market landscape and the Nivolumab biosimilar programme delivered through PTC Oncology and technical partner TAC.
PTC-Oncology-Investor-Deck.pdf · 0.60 MB
USD 45B
Nivolumab market by 2033
7.5% CAGR
Growth rate 2026–2033
£17.4M
Total programme investment
01
The Opportunity
Immuno-oncology monoclonal antibodies are among the most impactful therapeutic classes in modern medicine. Nivolumab alone was valued at USD 25 billion in 2024 and is projected to reach USD 45 billion by 2033. PTC Oncology is positioned to develop and manufacture a UK-originated biosimilar to serve this global demand.
02
Why Oncology
Cancer remains one of the leading causes of mortality worldwide. Advances in monoclonal antibody therapy have transformed patient outcomes, but access remains constrained by cost and manufacturing complexity. Biosimilar development is a direct route to expanding access whilst building durable commercial value.
03
Market Opportunity
Nivolumab holds market-defining indications including melanoma, non-small cell lung cancer, and head and neck cancers. Global demand spans North America, Europe, Asia-Pacific and beyond — including strong GCC uptake estimated at £71M in annual sales.
04
Competitive Advantages
Deep formulation expertise across 20+ launched injectables, an established technical partnership with The Antibody Company (TAC), location at Sci-Tech Daresbury, and an integrated capability set from cell line to cGMP manufacturing readiness.
05
Technology Platform
Eight-stage integrated platform — Research → Formulation → Development → Optimisation → Scale-up → Manufacturing → Quality → Commercialisation — engineered for both small molecules and biologics.
06
Research Strategy
Lead Nivolumab programme progressed through cell line development (~8 months, ~£1.4M) with subsequent clinical trial entry and Phase I investment tranches. Additional oncology mAb targets pipelined for parallel development.
07
Commercial Strategy
MHRA marketing authorisation for the UK, with staged rollout across the EU and Gulf Cooperation Council markets. Strategic partnerships to access North American and Asia-Pacific distribution.
08
Pipeline Roadmap
Placeholder — Nivolumab lead programme, with additional oncology monoclonal antibody biosimilars sequenced behind. Detailed pipeline available under NDA.
09
Growth Strategy
Expand development capacity, scale cGMP manufacturing readiness, broaden pipeline coverage, and build long-term supply partnerships with pharmaceutical manufacturers, NHS trusts and international distributors.
10
Leadership
Founder & Chief Scientific Officer Dr. Sameh Qanadilo brings 20+ years of pharmaceutical formulation and process development leadership, with Project Director Eric Wagner (TAC) leading antibody science.
11
Future Expansion
Extend the platform to combination immuno-oncology therapies, antibody-drug conjugates, and next-generation biosimilars — with potential for international manufacturing partnerships.
12
Corporate Governance
Placeholder — governance framework, board composition and advisory board information available on request during diligence.
13
Milestones
Placeholder — key operational, scientific and commercial milestones will be published as programmes progress.
14
Funding Journey
Placeholder — historical and forthcoming funding rounds, structure and use of proceeds available to qualified investors under NDA.
Investor enquiries